Rigel Pharmaceuticals

IPO

Novel therapies to enhance patient lives

Public · South San Francisco, United States · Founded 1996 · $21.4M raised

Employees
51–200
Founded
1996
Business Model
B2B
Website
rigel.com
Total Funding
$21.4M
Last Round
$14.9M Venture RoundJan 1999
Rounds
2
Type
Public

About

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing, and providing novel small-molecule drugs that significantly improve the lives of patients with hematologic disorders and cancer. Rigel's commercial products include TAVALISSE (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for relapsed or refractory acute myeloid leukemia with IDH1 mutations, and Gavreto (pralsetinib) for certain RET-altered non-small cell lung cancers. The company is headquartered in South San Francisco, California.

Summary

Rigel Pharmaceuticals is a Healthcare company based in South San Francisco, United States, founded in 1996. It has raised $21.4M in total across 2 rounds, most recently a $14.9M Venture Round round in Jan 1999.

Tech & App Stack

3 technologies & apps tracked

Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.

Sign up to view the funding chart

Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.

Funding History

Credit LineCredit LineOct 2019
$10.0M

Sign up to see all 6 rounds

Full funding history, per-round amounts, and investor participation.

Similar Companies